CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
20 hedge funds and large institutions have $8.14M invested in CASI Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 5 closing their positions.
320% more capital invested
Capital invested by funds: $1.94M → $8.14M (+$6.2M)
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
7.24% more ownership
Funds ownership: 2.63% → 9.87% (+7.2%)
13% less funds holding
Funds holding: 23 → 20 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
75% less call options, than puts
Call options by funds: $2K | Put options by funds: $8K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$5.66M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$366K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$197K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$147K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$21.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Howland Capital Management
Boston,
Massachusetts
|
-$82.9K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$18.5K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$5K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$550 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$162 |
CASI Hedge Fund Activity: Q3 2024 in Review
20 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q3 2024, worth a combined $8.14M — up 320% from $1.94M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CASI and 2 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was VR Adviser, adding an estimated $5.66M. The largest seller was Howland Capital Management, exiting entirely with an estimated $82.9K sold.
- 20 institutional investors held CASI Pharmaceuticals (CASI) as of Q3 2024, down from 23 in Q2 2024.
- Funds reported $8.14M of CASI Pharmaceuticals stock for Q3 2024, up 320% quarter-over-quarter.
- 2 funds opened new CASI Pharmaceuticals positions in Q3 2024 and 5 closed out, a net change of -3 holders.
- The largest CASI Pharmaceuticals buyer in Q3 2024 was VR Adviser, an estimated $5.66M added.
- The largest CASI Pharmaceuticals seller in Q3 2024 was Howland Capital Management, an estimated $82.9K sold.
Based on aggregated 13F filings for Q3 2024.